Side-by-side · Research reference
MazdutidevsSelank
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 3HUMAN-REVIEWED19/62 cited
BHuman-MechanisticAUTO-DRAFTED11/40 cited
Mazdutide
GLP-1/Glucagon Dual Agonist · Oxyntomodulin Analogue · Phase 3
SQ · Abdomen · Once WeeklyJi 2026
Selank
Anxiolytic + Cognitive · Russian Pharma
Intranasal · 2–3×/day during stress / cognitive demand
01Mechanism of Action
Parameter
Mazdutide
Selank
Primary target
GLP-1 receptor and glucagon receptorAbdul 2026Elmendorf 2026
Monoamine system (serotonin / GABA modulation) + immunomodulation via tuftsin domainZaderej 2014
Pathway
Dual agonism: GLP-1R → satiety, insulin secretion, gastric emptying delay; GCGR → hepatic lipolysis, energy expenditure, thermogenesisElmendorf 2026Abulehia 2026
Tuftsin-derived immune signaling + CNS monoamine modulation → reduced anxiety + improved mood / cognitionMedvedev 2007
Downstream effect
Weight loss via appetite suppression (GLP-1 axis) and increased energy expenditure (glucagon axis); improved glycemic control in T2D
Anxiolytic + cognitive enhancement; immunomodulation via increased IL-6 + IFN-γMedvedev 2007Zaderej 2014
Feedback intact?
Yes — physiological receptor-mediated signaling preserved
No GABA-receptor binding; no dependence reportedMedvedev 2007
Origin
Synthetic oxyntomodulin analogue — endogenous peptide with dual GLP-1/glucagon activity
Synthetic 7-AA peptide derived from human tuftsin (immune-system tetrapeptide)Zaderej 2014
Antibody development
—
—
02Dosage Protocols
Parameter
Mazdutide
Selank
Phase 2 studied dose
—
Dose escalation
3 mg → 6 mg → 9 mg (titration schedule in trials)
Gradual escalation to minimize GI side effects.
—
Evidence basis
Human-mechanistic + Russian clinical trialsMedvedev 2007
Duration (trials)
24–48 weeks
—
Population
Non-diabetic adults BMI ≥30 kg/m² or ≥27 kg/m² with comorbidities
—
Lower / starter dose
—
75 mcg / dose
Duration
—
10–14 day cycles, repeated as needed
Reconstitution
—
Pre-formulated nasal spray (commercial); research vial: bacteriostatic water
Timing
—
Morning + early afternoon preferred
Half-life
—
Short (minutes plasma); CNS effect lasts ~3 hr
03Metabolic / Fat Loss Evidence
Parameter
Mazdutide
Selank
Percentage body weight loss
12.4% (pooled meta-analysis, 9 mg dose)
95% CI: -16.15% to -8.68%, random-effects model.Azam 2026
—
Responder rate (≥10% loss)
Not explicitly reported in available abstracts
—
Visceral fat
Expected benefit from glucagon-mediated lipolysis (not quantified in abstracts)
—
Glycemic improvement
HbA1c reduction in T2D cohort (Phase 3 DREAMS-3)
—
Key publications
Ji et al. Med 2026 · Azam et al. Diab Obes Metab 2026 · Luo et al. Contemp Clin Trials 2026
—
04Side Effects & Safety
Parameter
Mazdutide
Selank
Gastrointestinal symptoms
Nausea, vomiting, diarrhea (most common, GLP-1 effect)
—
Injection site reactions
Erythema, pruritus, local discomfort
—
Hypoglycemia
Low risk in non-diabetic cohort; monitor in T2D with insulin or sulfonylureas
—
Cardiovascular effects
Increased heart rate (glucagon effect, transient)
—
Pancreatitis risk
Theoretical (incretin class effect); monitor amylase/lipase if abdominal pain
—
Thyroid C-cell tumors
Black box warning for GLP-1 class (rodent data); human relevance unclear
—
Gallbladder disease
Cholelithiasis, cholecystitis (rapid weight loss effect)
—
Tolerability
Generally well-tolerated; GI effects diminish with dose titration
—
Nasal irritation
—
Mild burning or congestion (transient)
Cognitive impairment
—
None — opposite effect (enhancement)
Allergic reaction
—
Rare hypersensitivity
Long-term safety
—
Limited Western RCT data
Pregnancy / OB
—
Avoid — insufficient data
Absolute Contraindications
Mazdutide
- ·Personal or family history of medullary thyroid carcinoma
- ·Multiple endocrine neoplasia syndrome type 2 (MEN 2)
- ·Hypersensitivity to mazdutide or excipients
- ·Pregnancy
Selank
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to peptide
Relative Contraindications
Mazdutide
- ·History of pancreatitis
- ·Severe gastroparesis or GI motility disorders
- ·Diabetic retinopathy (monitor, risk of worsening with rapid glycemic change)
- ·Renal impairment (limited data, use with caution)
Selank
- ·Active autoimmune disease (theoretical via immunomodulation)
05Administration Protocol
Parameter
Mazdutide
Selank
1. Preparation
Supplied as pre-filled pen or reconstituted vial (per manufacturer instructions). Inspect solution — should be clear, colorless to pale yellow. Discard if cloudy or particulate matter present.
Pre-formulated nasal spray (commercial) or research vial reconstituted with bacteriostatic water.
2. Injection site
Subcutaneous — abdomen preferred, also thigh or upper arm. Rotate sites weekly. Avoid areas with scarring, moles, or active inflammation.
Intranasal — 1–3 sprays per nostril per dose. Tilt head slightly back.
3. Timing
Once weekly, same day each week. May be taken with or without food. If dose missed, administer within 3 days; if >3 days, skip and resume next scheduled dose.
Morning + early afternoon for cognitive demand; PRN for acute anxiety.
4. Storage
Refrigerate 2–8 °C. Do not freeze. May be kept at room temperature (<25 °C) for up to 14 days if needed. Protect from light.
Refrigerate after reconstitution; ≤30 days. Light-protected.
5. Needle technique
Use supplied needle or compatible insulin syringe (if reconstituting). Pinch skin, inject at 90° angle. Hold 5–10 seconds before withdrawing needle to prevent leakage.
Avoid co-administration with strong sedatives or other anxiolytics initially.